ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO909

SerpinA3K Is Abnormally Found in Urine of Patients with CKD from Different Etiologies

Session Information

Category: CKD (Non-Dialysis)

  • 1903 CKD (Non-Dialysis): Mechanisms

Authors

  • Sanchez-Navarro, Andrea, Molecular Physiology Unit, México, Mexico
  • Pérez-villalva, Rosalba, Molecular Physiology Unit, México, Mexico
  • Mejia-Vilet, Juan M., IIB UNAM/INCMNSZ, Mexico, Mexico
  • Carrillo Perez, Diego Luis, IIB UNAM/INCMNSZ, Mexico, Mexico
  • Gamba, Gerardo, Molecular Physiology Unit, México, Mexico
  • Bobadilla, Norma, Molecular Physiology Unit, México, Mexico
Background

We previously identified serpinA3K by high-resolution mass spectrometry as an early biomarker of acute kidney injury to CKD transition in rats.
This study was designed to determine whether serpinA3K could be abnormally detected in urine from CKD patients and to evaluate its specificity in kidney diseases, compared with urines from patients with other pathologies without renal dysfunction.

Methods

We included 74 patients with CKD of different etiologies such as: FSGS, class III, IV or V lupus nephritis (LN), ANCA associated vasculitis (AAV), and diabetic nephropathy (DN) that were compared with 10 healthy volunteers. In addition, we included 17 patients with other pathologies and normal renal function: hepatic cirrhosis (HC), pancreatitis (Pan), and rheumatoid arthritis (RA). SerpinA3K was evaluated in urine (Western blot) and in renal biopsies ( immunohistochemistry).

Results

In HC, Pan and RA patients without renal dysfunction urine serpinA3K was not detected. In Table 1 are the main results of the CKD patients. In addition, immunohistochemistry analysis showed that serpinA3K was expressed in tubular epithelial cells, and translocated from the cytoplasmic region to the luminal membrane in CKD patients.

Conclusion

Urinary serpinA3K was detected in all patients with CKD. Urine serpinA3K titers closely correlated with the renal fibrosis observed by histopathological analysis (p<0.0001). Moreover, this biomarker was able to differentiate between class III/IV and class V LN, in spite of severe proteinuria in these patients. These results suggest that urine serpinA3K comes from damaged kidney cells and could be used as a specific biomarker of ongoing renal inflammation, fibrosis and therefore CKD.
SerpinA3K is found in the urine of CKD patients from different etiologies and correlates with renal fibrosis. SerpinA3K constitutes a specific promising CKD biomarker.

Funding

  • Government Support - Non-U.S.